These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 30598332)

  • 1. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome.
    Geethakumari PR; Mille P; Gulati R; Nagalla S
    Transfus Apher Sci; 2017 Jun; 56(3):400-403. PubMed ID: 28428030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.
    El-Husseini A; Hannan S; Awad A; Jennings S; Cornea V; Sawaya BP
    Am J Kidney Dis; 2015 Jan; 65(1):127-30. PubMed ID: 25446020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic microangiopathy due to primary antiphospholipid syndrome: successful treatment with eculizumab.
    Pala C; Parenti E; Vizzini G; Gianfreda D; Rossi GM
    J Nephrol; 2024 May; 37(4):1141-1145. PubMed ID: 37847369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature.
    Skoczynska M; Crowther MA; Chowaniec M; Ponikowska M; Chaturvedi S; Legault K
    Lupus; 2020 May; 29(6):631-639. PubMed ID: 32252584
    [No Abstract]   [Full Text] [Related]  

  • 10. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
    BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
    Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
    Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.
    Smith J; Hans V; Yacyshyn E; Rouhi A; Oliver M
    Rheumatol Int; 2024 Oct; 44(10):2213-2225. PubMed ID: 38502235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
    Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
    Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
    Sciascia S; Radin M; Yazdany J; Tektonidou M; Cecchi I; Roccatello D; Dall'Era M
    Rheumatol Int; 2017 Aug; 37(8):1249-1255. PubMed ID: 28258475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
    Kotzen ES; Roy S; Jain K
    Adv Chronic Kidney Dis; 2019 Sep; 26(5):376-386. PubMed ID: 31733722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
    Hadaya K; Ferrari-Lacraz S; Fumeaux D; Boehlen F; Toso C; Moll S; Martin PY; Villard J
    Am J Transplant; 2011 Nov; 11(11):2523-7. PubMed ID: 21831149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.
    Carrara C; Mataj B; Gastoldi S; Ruggenenti P; Sciascia S; Roccatello D
    Front Immunol; 2024; 15():1460317. PubMed ID: 39318635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.